Lexaria Bioscience (LEXX) Competitors $0.97 +0.01 (+1.04%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEXX vs. GNTA, XCUR, CTMX, TELO, EPIX, STRO, PYXS, JSPR, IGMS, and MNOVShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Genenta Science (GNTA), Exicure (XCUR), CytomX Therapeutics (CTMX), Telomir Pharmaceuticals (TELO), ESSA Pharma (EPIX), Sutro Biopharma (STRO), Pyxis Oncology (PYXS), Jasper Therapeutics (JSPR), IGM Biosciences (IGMS), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. Genenta Science Exicure CytomX Therapeutics Telomir Pharmaceuticals ESSA Pharma Sutro Biopharma Pyxis Oncology Jasper Therapeutics IGM Biosciences MediciNova Genenta Science (NASDAQ:GNTA) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation. Do analysts rate GNTA or LEXX? Genenta Science currently has a consensus target price of $25.00, suggesting a potential upside of 470.13%. Lexaria Bioscience has a consensus target price of $7.00, suggesting a potential upside of 621.65%. Given Lexaria Bioscience's higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Genenta Science.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer GNTA or LEXX? Genenta Science and Lexaria Bioscience both received 7 outperform votes by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 87.50% of users gave Genenta Science an outperform vote. CompanyUnderperformOutperformGenenta ScienceOutperform Votes787.50% Underperform Votes112.50%Lexaria BioscienceOutperform Votes7100.00% Underperform VotesNo Votes Does the media favor GNTA or LEXX? In the previous week, Genenta Science had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 1 mentions for Genenta Science and 0 mentions for Lexaria Bioscience. Genenta Science's average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score. Company Overall Sentiment Genenta Science Neutral Lexaria Bioscience Neutral Which has more risk & volatility, GNTA or LEXX? Genenta Science has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Do institutionals & insiders have more ownership in GNTA or LEXX? 15.1% of Genenta Science shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 26.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is GNTA or LEXX more profitable? Genenta Science has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,473.04%. Genenta Science's return on equity of 0.00% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Genenta ScienceN/A N/A N/A Lexaria Bioscience -1,473.04%-88.88%-83.59% Which has stronger earnings & valuation, GNTA or LEXX? Lexaria Bioscience has higher revenue and earnings than Genenta Science. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenenta ScienceN/AN/A-$12.60MN/AN/ALexaria Bioscience$525.92K32.39-$5.80M-$0.59-1.64 SummaryGenenta Science beats Lexaria Bioscience on 6 of the 11 factors compared between the two stocks. Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition Export to ExcelMetricLexaria BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.03M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-1.949.0426.7819.69Price / Sales32.39253.23386.97118.34Price / CashN/A65.8538.2534.62Price / Book2.026.406.744.50Net Income-$5.80M$143.98M$3.23B$248.32M7 Day Performance-5.83%1.90%1.49%-0.03%1 Month Performance-33.56%4.01%11.47%12.72%1 Year Performance-64.73%-3.00%16.57%7.38% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience2.0166 of 5 stars$0.97+1.0%$7.00+621.6%-67.9%$17.03M$525,923.00-1.947Gap UpGNTAGenenta Science1.4984 of 5 stars$4.13-5.0%$25.00+506.1%+38.7%$75.45MN/A0.007XCURExicure1.4631 of 5 stars$11.86+3.7%N/A+2,082.5%$74.93M$500,000.00-5.7350Gap UpCTMXCytomX Therapeutics4.2375 of 5 stars$2.13+129.4%$4.25+99.5%+9.1%$74.85M$138.10M12.53170Analyst RevisionHigh Trading VolumeTELOTelomir Pharmaceuticals1.7141 of 5 stars$2.51+0.8%$15.00+497.6%-62.6%$74.71MN/A-4.331News CoverageEPIXESSA Pharma2.005 of 5 stars$1.68-2.3%$9.50+465.5%-73.2%$74.57MN/A-2.4350Positive NewsSTROSutro Biopharma4.395 of 5 stars$0.87-0.2%$6.63+661.5%-81.5%$73.40M$62.04M-0.54240News CoverageAnalyst ForecastPYXSPyxis Oncology1.4179 of 5 stars$1.15+7.5%$9.00+682.6%-71.3%$71.24M$16.15M-1.1260Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGap UpJSPRJasper Therapeutics2.1532 of 5 stars$4.74+4.9%$62.50+1,218.6%-79.1%$71.20MN/A-1.0020IGMSIGM Biosciences4.2751 of 5 stars$1.19+5.3%$5.50+362.2%-86.0%$71.13M$2.68M-0.33190Positive NewsMNOVMediciNova1.1053 of 5 stars$1.45-1.4%$9.00+520.7%+0.0%$71.12M$1M-6.3010 Related Companies and Tools Related Companies GNTA Competitors XCUR Competitors CTMX Competitors TELO Competitors EPIX Competitors STRO Competitors PYXS Competitors JSPR Competitors IGMS Competitors MNOV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEXX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LEXX Stock Free LEXX Stock Alerts